CoreCap Advisors LLC Increases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CoreCap Advisors LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 36.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,831 shares of the biopharmaceutical company’s stock after purchasing an additional 4,242 shares during the quarter. CoreCap Advisors LLC’s holdings in Halozyme Therapeutics were worth $757,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Venturi Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $69,000. Shaker Investments LLC OH boosted its position in Halozyme Therapeutics by 12.3% in the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company’s stock worth $3,601,000 after purchasing an additional 8,249 shares during the last quarter. Foster & Motley Inc. increased its position in shares of Halozyme Therapeutics by 118.6% during the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock valued at $1,113,000 after purchasing an additional 12,630 shares during the last quarter. Jennison Associates LLC bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $731,000. Finally, Koa Wealth Management LLC boosted its holdings in shares of Halozyme Therapeutics by 10.6% in the 4th quarter. Koa Wealth Management LLC now owns 82,407 shares of the biopharmaceutical company’s stock worth $3,940,000 after buying an additional 7,924 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Friday, April 25th. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a report on Wednesday. Benchmark lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. increased their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $63.78.

Halozyme Therapeutics Trading Down 2.8 %

Shares of HALO opened at $65.86 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51. The stock has a market cap of $8.14 billion, a PE ratio of 19.20, a P/E/G ratio of 0.42 and a beta of 1.26. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The business’s 50-day moving average price is $61.45 and its 200-day moving average price is $55.80.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same quarter in the prior year, the firm posted $0.79 EPS. Halozyme Therapeutics’s revenue was up 35.2% on a year-over-year basis. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares in the company, valued at $1,972,629.59. The trade was a 12.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. The trade was a 5.12 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,697 shares of company stock valued at $1,276,552. Company insiders own 2.90% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.